Precipio, Inc. (PRPO) Stock Score, Valuation & Financial Research
Precipio, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for PRPO
Precipio, Inc. currently has a Wall Street Score of 29/100. The stored market price is $27.32. Its financial score is 36/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Precipio, Inc. does
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $27.32
- Market capitalization:
- $48.7M
- Revenue:
- $26.1M
- Net income:
- $-922K
- Free cash flow:
- $359K
- Cash:
- $2.6M
- Total debt:
- $3.5M
- EPS:
- -0.23
- Financial score:
- 36/100
- Valuation score:
- 0/100
- Revenue score:
- 35/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $359K, showing positive cash generation.
- The balance sheet shows $2.6M of cash versus $3.5M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PRPO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.